Imperial College London
Portrait Picture

ProfessorPaolaPiccini

Faculty of Medicine, Department of Brain Sciences

Emeritus Professor - Neurology
 
 
 
//

Contact

 

+44 (0)20 3313 3773paola.piccini

 
 
//

Assistant

 

Ms Hyacinth Henry +44 (0)20 3313 3172

 
//

Location

 

U107BBlock B Hammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Parker:2019:10.1038/s41591-019-0507-2,
author = {Parker, RA and TRANSEURO, consortium and Piccini, P},
doi = {10.1038/s41591-019-0507-2},
journal = {Nature Medicine},
pages = {1045--1053},
title = {Designing stem-cell-based dopamine cell replacement trials for Parkinson's disease},
url = {http://dx.doi.org/10.1038/s41591-019-0507-2},
volume = {25},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Clinical studies of Parkinson’s disease (PD) using a dopamine cell replacment strategy have been tried for more than 30 years. The outcomes following transplantation of human fetal ventral mesencephalic tissue (hfVM) have been variable, with some patients coming off their anti-PD treatment for many years and others not responding and/or developing significant side effects, including graft-induced dyskinesia. This led to a re-appraisal of the best way to do such trials, which resulted in a new European-Union-funded allograft trial with fetal dopamine cells across several centers in Europe. This new trial, TRANSEURO (NCT01898390), is an open-label study in which some individuals in a large observational cohort of patients with mild PD who were undergoing identical assessments were randomly selected to receive transplants of hfVM. The TRANSEURO trial is currently ongoing as researchers have completed both recruitment into a large multicenter observational study of younger onset early-stage PD and transplantation of hfVM in 11 patients. While completion of TRANSEURO is not expected until 2021, we feel that sharing the rationale for the design of TRANSEURO, along with the lessons we have learned along the way, can help inform researchers and facilitate planning of transplants of dopamine-producing cells derived from human pluripotent stem cells for future clinical trials.
AU  - Parker,RA
AU  - TRANSEURO,consortium
AU  - Piccini,P
DO  - 10.1038/s41591-019-0507-2
EP  - 1053
PY  - 2019///
SN  - 1078-8956
SP  - 1045
TI  - Designing stem-cell-based dopamine cell replacement trials for Parkinson's disease
T2  - Nature Medicine
UR  - http://dx.doi.org/10.1038/s41591-019-0507-2
UR  - http://hdl.handle.net/10044/1/73170
VL  - 25
ER  -
Download